
    
      This was a randomized, blinded, double-dummy, parallel-group 12-week study to assess the
      efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.)
      in patients with chronic obstructive pulmonary disease (COPD).
    
  